Biogen Idec Selects Evotec OAI as a Service Provider for Process Research & Development

Evotec OAI AG a leading partner for integrated, high-value-added drug discovery and development solutions, today announced that Biogen Idec has selected Evotec OAI as one of its service providers for chemical process research and development and cGMP manufacturing. The companies have expanded their relationship under a master services agreement. The objective of the collaboration is to progress one of Biogen Idec's development candidates rapidly through preclinical testing into clinical trials through provision of Evotec OAI's integrated chemical and pharmaceutical development platform, EVOdevelop(TM). Evotec OAI has built a strong reputation and track record through its collaboration with Biogen Idec, which began over 5 years ago. The companies have worked together on a variety of projects including novel route selection all the way through to scale-up and cGMP manufacturing using Evotec OAI's world-class expertise in Active Pharmaceutical Ingredient development and manufacturing. Dr Mario Polywka, President Chemical and Pharmaceutical Development Division at Evotec OAI, said: "We are extremely delighted that Biogen Idec continue to work with Evotec OAI as a partner to progress their small molecule development candidate. Our long term partnership with Biogen Idec is a strong validation of our chemical development capability and we look forward to building on our successful collaboration."

Other news from the department business & finance

Most read news

More news from our other portals

Discover the latest developments in battery technology!